You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRizatriptan
Accession NumberDB00953  (APRD00008)
TypeSmall Molecule
GroupsApproved
Description

Rizatriptan is a triptan drug used for the treatment of migraine headaches. It is a selective 5-hydroxytryptamine1 receptor subtype agonist.

Structure
Thumb
Synonyms
MK 462 free base
N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethanamine
N,N-Dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine
Risatriptan
Rizatriptan benzoat
Rizatriptan benzoate
Rizatriptanum
External Identifiers
  • MK 462 Free Base
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Rizatriptantablet5 mgoralActavis Pharma CompanyNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Act Rizatriptantablet10 mgoralActavis Pharma Company2012-06-14Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Act Rizatriptan ODTtablet (orally disintegrating)10 mgoralActavis Pharma Company2012-01-30Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Act Rizatriptan ODTtablet (orally disintegrating)5 mgoralActavis Pharma Company2012-01-30Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Auro-rizatriptantablet10 mgoralAuro Pharma IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Auro-rizatriptan ODTtablet (orally disintegrating)10 mgoralAuro Pharma IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Auro-rizatriptan ODTtablet (orally disintegrating)5 mgoralAuro Pharma IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Dom-rizatriptan Rdttablet (orally disintegrating)5 mgoralDominion PharmacalNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Dom-rizatriptan Rdttablet (orally disintegrating)10 mgoralDominion Pharmacal2013-05-20Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ipg-rizatriptantablet10 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ipg-rizatriptantablet5 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Jamp-rizatriptantablet5 mgoralJamp Pharma Corporation2012-03-26Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Jamp-rizatriptantablet10 mgoralJamp Pharma Corporation2012-03-26Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Jamp-rizatriptan Irtablet10 mgoralJamp Pharma Corporation2014-09-25Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Jamp-rizatriptan Irtablet5 mgoralJamp Pharma Corporation2014-09-25Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mar-rizatriptantablet10 mgoralMarcan Pharmaceuticals Inc2012-05-03Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mar-rizatriptantablet5 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Maxalttablet5 mg/1oralMerck Sharp & Dohme Corp.1998-06-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Maxalttablet10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2007-08-24Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Maxalttablet10 mg/1oralRebel Distributors Corp1998-06-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Maxalttablet10 mg/1oralSTAT Rx USA LLC1998-06-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Maxalttablet10 mg/1oralPhysicians Total Care, Inc.2007-08-24Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Maxalttablet5 mgoralMerck Canada Inc1999-08-312013-07-15Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Maxalttablet10 mgoralMerck Canada Inc1999-08-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Maxalttablet10 mg/1oralMerck Sharp & Dohme Corp.1998-06-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Maxalt Rpdtablet (orally disintegrating)5 mgoralMerck Canada Inc2000-05-05Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Maxalt Rpdtablet (orally disintegrating)10 mgoralMerck Canada Inc1999-08-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Maxalt-mlttablet, orally disintegrating10 mg/1oralPhysicians Total Care, Inc.2009-12-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Maxalt-mlttablet, orally disintegrating5 mg/1oralSTAT Rx USA LLC1998-06-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Maxalt-mlttablet, orally disintegrating10 mg/1oralMerck Sharp & Dohme Corp.1998-06-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Maxalt-mlttablet, orally disintegrating5 mg/1oralMerck Sharp & Dohme Corp.1998-06-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mint-rizatriptan ODTtablet (orally disintegrating)5 mgoralMint Pharmaceuticals Inc2015-06-10Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mint-rizatriptan ODTtablet (orally disintegrating)10 mgoralMint Pharmaceuticals Inc2015-06-10Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mylan-rizatriptantablet10 mgoralMylan Pharmaceuticals UlcNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mylan-rizatriptantablet5 mgoralMylan Pharmaceuticals UlcNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mylan-rizatriptan ODTtablet (orally disintegrating)10 mgoralMylan Pharmaceuticals Ulc2012-01-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mylan-rizatriptan ODTtablet (orally disintegrating)5 mgoralMylan Pharmaceuticals Ulc2012-01-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nat-rizatriptantablet10 mgoralNatco Pharma (Canada) IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nat-rizatriptantablet5 mgoralNatco Pharma (Canada) IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nat-rizatriptan ODTtablet (orally disintegrating)10 mgoralNatco Pharma (Canada) Inc2015-02-17Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nat-rizatriptan ODTtablet (orally disintegrating)5 mgoralNatco Pharma (Canada) Inc2015-02-17Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-rizatriptan Rdttablet (orally disintegrating)5 mgoralPharmascience Inc2012-10-30Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-rizatriptan Rdttablet (orally disintegrating)10 mgoralPharmascience Inc2012-10-30Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Q-rizatriptan ODTtablet (orally disintegrating)10 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Q-rizatriptan ODTtablet (orally disintegrating)5 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Riva-rizatriptan ODTtablet (orally disintegrating)10 mgoralLaboratoire Riva Inc2014-06-12Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Riva-rizatriptan ODTtablet (orally disintegrating)5 mgoralLaboratoire Riva Inc2014-06-12Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Rizatriptantablet5 mgoralJubilant Generics LimitedNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Rizatriptantablet10 mgoralJubilant Generics LimitedNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Rizatriptan Benzoatetablet, orally disintegrating10 mg/1oralPar Pharmaceutical Inc.1998-06-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet, orally disintegrating5 mg/1oralPar Pharmaceutical Inc.1998-06-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet10 mg/1oralPar Pharmaceutical Inc.1998-06-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet5 mg/1oralPar Pharmaceutical Inc.1998-06-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan ODTtablet (orally disintegrating)10 mgoralSanis Health Inc2015-07-23Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Rizatriptan ODTtablet (orally disintegrating)5 mgoralSivem Pharmaceuticals Ulc2015-10-07Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Rizatriptan ODTtablet (orally disintegrating)5 mgoralSanis Health Inc2015-07-23Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Rizatriptan ODTtablet (orally disintegrating)10 mgoralAbri Pharmaceuticals IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Rizatriptan ODTtablet (orally disintegrating)5 mgoralAbri Pharmaceuticals IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Rizatriptan ODTtablet (orally disintegrating)10 mgoralSivem Pharmaceuticals Ulc2015-10-07Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Rizatriptan Rdttablet (orally disintegrating)5 mgoralPro Doc Limitee2013-11-28Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Rizatriptan Rdttablet (orally disintegrating)10 mgoralPro Doc Limitee2013-11-28Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Sandoz Rizatriptan ODTtablet (orally disintegrating)5 mgoralSandoz Canada Incorporated2012-01-30Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Sandoz Rizatriptan ODTtablet (orally disintegrating)10 mgoralSandoz Canada Incorporated2012-01-30Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Teva-rizatriptantablet10 mgoralTeva Canada LimitedNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Teva-rizatriptantablet5 mgoralTeva Canada LimitedNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Teva-rizatriptan ODTtablet (orally disintegrating)10 mgoralTeva Canada Limited2014-11-04Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Teva-rizatriptan ODTtablet (orally disintegrating)5 mgoralTeva Canada Limited2014-11-04Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Van-rizatriptantablet10 mgoralVanc Pharmaceuticals Inc2015-07-23Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Van-rizatriptantablet5 mgoralVanc Pharmaceuticals Inc2015-07-23Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Van-rizatriptan ODTtablet (orally disintegrating)10 mgoralVanc Pharmaceuticals IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Van-rizatriptan ODTtablet (orally disintegrating)5 mgoralVanc Pharmaceuticals IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-rizatriptantablet10 mgoralApotex Inc2012-09-27Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-rizatriptantablet5 mgoralApotex Inc2013-03-06Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-rizatriptan Rpdtablet (orally disintegrating)10 mgoralApotex Inc2013-09-10Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-rizatriptan Rpdtablet (orally disintegrating)5 mgoralApotex Inc2013-09-10Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Rizatriptantablet, film coated10 mg/1oralREMEDYREPACK INC.2015-06-08Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptantablet, film coated5 mg/1oralMacleods Pharmaceuticals Limited2014-03-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptantablet, film coated10 mg/1oralPreferred Pharmaceuticals Inc.2015-08-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptantablet, film coated10 mg/1oralMacleods Pharmaceuticals Limited2014-03-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet, orally disintegrating10 mg/1oralPreferred Pharmaceuuticals, Inc.2013-10-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet, orally disintegrating10 mg/1oralMacleods Pharmaceuticals Limited2014-09-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet, orally disintegrating5 mg/1oralJubilant Cadista Pharmaceuticals Inc.2014-03-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet5 mg/1oralTeva Pharmaceuticals USA Inc2013-02-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet, orally disintegrating10 mg/1oralSandoz Inc2013-07-02Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet, orally disintegrating5 mg/1oralBreckenridge Pharmaceutical, Inc.2013-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet10 mg/1oralGlenmark Pharmaceuticals Inc., Usa2012-12-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet10 mg/1oralCitron Pharma LLC2012-12-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet, orally disintegrating10 mg/1oralREMEDYREPACK INC.2014-09-09Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet, orally disintegrating5 mg/1oralSandoz Inc2013-07-02Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet10 mg/1oralBreckenridge Pharmaceutical, Inc.2012-12-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet5 mg/1oralGlenmark Pharmaceuticals Inc., Usa2012-12-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet10 mg/1oralCamber Pharmaceuticals, Inc.2015-01-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet5 mg/1oralCitron Pharma LLC2012-12-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet, orally disintegrating10 mg/1oralApotex Corp2013-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet, orally disintegrating10 mg/1oralMylan Pharmaceuticals Inc.2012-12-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet5 mg/1oralBreckenridge Pharmaceutical, Inc.2012-12-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet, orally disintegrating10 mg/1oralAurobindo Pharma Limited2013-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet5 mg/1oralCamber Pharmaceuticals, Inc.2015-01-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet, orally disintegrating10 mg/1oralCitron Pharma LLC2013-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet, orally disintegrating5 mg/1oralApotex Corp2013-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet, orally disintegrating5 mg/1oralMylan Pharmaceuticals Inc.2012-12-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet10 mg/1oralSun Pharma Global FZE2013-01-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet10 mg/1oralHeritage Pharmaceuticals Inc.2013-12-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet, orally disintegrating5 mg/1oralCitron Pharma LLC2013-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet, orally disintegrating5 mg/1oralAurobindo Pharma Limited2013-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet10 mg/1oralMylan Pharmaceuticals Inc.2012-12-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet10 mg/1oralCipla USA Inc.2015-03-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet5 mg/1oralSun Pharma Global FZE2013-01-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet10 mg/1oralApotex Corp2012-12-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet5 mg/1oralHeritage Pharmaceuticals Inc.2013-12-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet, orally disintegrating10 mg/1oralPhysicians Total Care, Inc.2013-01-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet10 mg/1oralAurobindo Pharma Limited2012-12-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet5 mg/1oralMylan Pharmaceuticals Inc.2012-12-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet5 mg/1oralCipla USA Inc.2013-03-26Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet5 mg/1oralMesource Pharmaceuticals2012-12-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet5 mg/1oralApotex Corp2012-12-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet10 mg/1oralPhysicians Total Care, Inc.2013-01-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet5 mg/1oralAurobindo Pharma Limited2012-12-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet10 mg/1oralSandoz Inc2013-02-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet, orally disintegrating10 mg/1oralGlenmark Pharmaceuticals Inc., Usa2013-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet, orally disintegrating5 mg/1oralMacleods Pharmaceuticals Limited2014-09-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet10 mg/1oralJubilant Cadista Pharmaceuticals Inc.2014-03-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet10 mg/1oralMedsource Pharmaceuticals2012-12-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet, orally disintegrating10 mg/1oralJubilant Cadista Pharmaceuticals Inc.2012-03-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet10 mg/1oralTeva Pharmaceuticals USA Inc2013-02-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet, orally disintegrating10 mg/1oralProficient Rx LP2013-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet5 mg/1oralSandoz Inc2013-02-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet, orally disintegrating10 mg/1oralBreckenridge Pharmaceutical, Inc.2013-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet, orally disintegrating5 mg/1oralGlenmark Pharmaceuticals Inc., Usa2013-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rizatriptan Benzoatetablet5 mg/1oralJubilant Cadista Pharmaceuticals Inc.2013-03-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
Maxalt MLTNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII51086HBW8G
CAS number145202-66-0
WeightAverage: 269.3449
Monoisotopic: 269.164045633
Chemical FormulaC15H19N5
InChI KeyInChIKey=ULFRLSNUDGIQQP-UHFFFAOYSA-N
InChI
InChI=1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3
IUPAC Name
dimethyl({2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethyl})amine
SMILES
CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as tryptamines and derivatives. These are compounds containing the tryptamine backbone, which is structurally characterized by an indole ring subsituted at the 3-position by an ethanamine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIndoles and derivatives
Sub ClassTryptamines and derivatives
Direct ParentTryptamines and derivatives
Alternative Parents
Substituents
  • Tryptamine
  • Indole
  • Aralkylamine
  • Benzenoid
  • Substituted pyrrole
  • Heteroaromatic compound
  • 1,2,4-triazole
  • Pyrrole
  • Azole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor treatment of acute migraine attacks with or without aura.
PharmacodynamicsRizatriptan is a selective agonist of serotonin (5-hydroxytryptamine; 5-HT) type 1B and 1D receptors. It is structurally and pharmacologically related to other selective 5-HT1B/1D receptor agonists and has only a weak affinity for 5-HT1A, 5-HT5A, and 5-HT7 receptors and no significant affinity or pharmacological activity at 5-HT2, 5-HT3 or 5-HT4 receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Rizatriptan also activates 5-HT1 receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Rizatriptan in humans.
Mechanism of actionThree distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT1B receptor agonism.
AbsorptionRapid following oral administration. Bioavailability is 45%. Food has no effect on the bioavailability of rizatriptan. However, administering rizatriptan with food will delay by 1 hour the time to reach peak plasma concentration. The rate of absorption is not affected by the presence of a migraine attack.
Volume of distribution
  • 140 L [male]
  • 110 L [female]
Protein binding14%
Metabolism

Rizatriptan is metabolized by monoamine oxidase A isoenzyme (MAO-A) to an inactive indole acetic acid metabolite. In addition, several other inactive metabolites are formed. An active metabolite, N-monodesmethyl-rizatriptan, with pharmacological activity similar to that of the parent compound has been identified in small concentrations (14%) in the plasma.

SubstrateEnzymesProduct
Rizatriptan
Not Available
N-monodesmethyl-rizatriptanDetails
Route of eliminationApproximately 14% of an oral dose is excreted in urine as unchanged rizatriptan while 51% is excreted as indole acetic acid metabolite, indicating substantial first pass metabolism.
Half life2-3 hours
ClearanceNot Available
ToxicitySymptoms of overdose include dizziness, fainting, heart and blood vessel problems, high blood pressure, loss of bowel and bladder control, slow heartbeat, and vomiting.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3
Gene symbol: GNB3
UniProt: P16520
rs5443 Not AvailableT AlleleBetter response to drug treatment17361120
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9406
Caco-2 permeable+0.5547
P-glycoprotein substrateSubstrate0.7478
P-glycoprotein inhibitor INon-inhibitor0.8752
P-glycoprotein inhibitor IINon-inhibitor0.7244
Renal organic cation transporterInhibitor0.7394
CYP450 2C9 substrateNon-substrate0.8572
CYP450 2D6 substrateNon-substrate0.6765
CYP450 3A4 substrateSubstrate0.5574
CYP450 1A2 substrateNon-inhibitor0.9149
CYP450 2C9 inhibitorNon-inhibitor0.9063
CYP450 2D6 inhibitorNon-inhibitor0.8913
CYP450 2C19 inhibitorNon-inhibitor0.9515
CYP450 3A4 inhibitorNon-inhibitor0.9688
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.956
Ames testAMES toxic0.5644
CarcinogenicityNon-carcinogens0.9133
BiodegradationNot ready biodegradable0.9439
Rat acute toxicity2.5433 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7051
hERG inhibition (predictor II)Non-inhibitor0.7265
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Merck and co inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral5 mg
Tabletoral10 mg/1
Tabletoral10 mg
Tabletoral5 mg/1
Tablet (orally disintegrating)oral10 mg
Tablet (orally disintegrating)oral5 mg
Tablet, orally disintegratingoral10 mg/1
Tablet, orally disintegratingoral5 mg/1
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral5 mg/1
Prices
Unit descriptionCostUnit
Maxalt 12 10 mg tablet Box333.27USD box
Maxalt 12 5 mg tablet Box333.27USD box
Maxalt-MLT 3 5 mg Dispersible Tablet Box286.96USD box
Maxalt 9 5 mg tablet Box203.46USD box
Maxalt 6 5 mg tablet Box107.44USD box
Maxalt-MLT 3 10 mg Dispersible Tablet Box83.32USD box
Maxalt mlt 10 mg tablet26.7USD tablet
Maxalt mlt 5 mg tablet26.7USD tablet
Maxalt 10 mg tablet25.31USD tablet
Maxalt 5 mg tablet22.98USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
Canada20601391998-12-012012-01-28
United States52985201995-06-292012-06-29
United States56021621994-02-112014-02-11
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point178-180 °CNot Available
water solubility42 mg/mL (for free base)Not Available
logP1.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.338 mg/mLALOGPS
logP1.67ALOGPS
logP1.77ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)17.24ChemAxon
pKa (Strongest Basic)9.56ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area49.74 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity93.13 m3·mol-1ChemAxon
Polarizability30 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Montserrat Armengol Asparo, Pere Dalmases Barjoan, “Process for preparing a rizatriptan.” U.S. Patent US20050148778, issued July 07, 2005.

US20050148778
General References
  1. Wellington K, Plosker GL: Rizatriptan: an update of its use in the management of migraine. Drugs. 2002;62(10):1539-74. Pubmed
  2. Wellington K, Jarvis B: Spotlight on rizatriptan in migraine. CNS Drugs. 2002;16(10):715-20. Pubmed
  3. Ikemoto F, Toru T, Aijima H, Natsumeda Y: [Rizatriptan (Maxalt), a new entity of triptan for migraine: pharmacology and therapeutic relevance] Nippon Yakurigaku Zasshi. 2004 Apr;123(4):295-302. Pubmed
  4. Villalon CM, Centurion D, Valdivia LF, De Vries P, Saxena PR: An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210. Pubmed
  5. Tfelt-Hansen P, De Vries P, Saxena PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000 Dec;60(6):1259-87. Pubmed
External Links
ATC CodesN02CC04
AHFS Codes
  • 28:32.28
PDB EntriesNot Available
FDA labelDownload (873 KB)
MSDSDownload (57.7 KB)
Interactions
Drug Interactions
Drug
AcepromazineThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Acepromazine.
AcetophenazineThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Acetophenazine.
AmisulprideThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Amisulpride.
AripiprazoleThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Aripiprazole.
BenzquinamideThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Benzquinamide.
CabergolineCabergoline may increase the vasoconstricting activities of Rizatriptan.
CarphenazineThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Carphenazine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Chlormezanone.
ChlorpromazineThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Chlorprothixene.
ClozapineThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Clozapine.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Rizatriptan.
DroperidolThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Droperidol.
DroxidopaRizatriptan may increase the hypertensive activities of Droxidopa.
FencamfamineThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Fencamfamine.
FlupentixolThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Fluphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Fluspirilene.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Rizatriptan.
GranisetronGranisetron may increase the serotonergic activities of Rizatriptan.
HaloperidolThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Haloperidol.
LoxapineThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Loxapine.
MesoridazineThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Mesoridazine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Methotrimeprazine.
MetoclopramideThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Metoclopramide.
MolindoneThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Molindone.
OlanzapineThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Olanzapine.
OndansetronThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Ondansetron.
PaliperidoneThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Paliperidone.
PerphenazineThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Perphenazine.
PhenelzineThe metabolism of Rizatriptan can be decreased when combined with Phenelzine.
PimozideThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Pimozide.
PiperacetazineThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Piperacetazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Prochlorperazine.
PromazineThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Promazine.
PropranololThe serum concentration of Rizatriptan can be increased when it is combined with Propranolol.
QuetiapineThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Quetiapine.
RemoxiprideThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Reserpine.
RisperidoneThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Risperidone.
SertindoleThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Sertindole.
SulpirideThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Sulpiride.
ThioridazineThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Thiothixene.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Rizatriptan.
TranylcypromineThe metabolism of Rizatriptan can be decreased when combined with Tranylcypromine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Triflupromazine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Ziprasidone.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

1. 5-hydroxytryptamine receptor 1D

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: agonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 1D P28221 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  2. Longmore J, Hargreaves RJ, Boulanger CM, Brown MJ, Desta B, Ferro A, Schofield WN, Taylor AA, Hill RG: Comparison of the vasoconstrictor properties of the 5-HT1D-receptor agonists rizatriptan (MK-462) and sumatriptan in human isolated coronary artery: outcome of two independent studies using different experimental protocols. Funct Neurol. 1997 Jan-Feb;12(1):3-9. Pubmed
  3. Longmore J, Boulanger CM, Desta B, Hill RG, Schofield WN, Taylor AA: 5-HT1D receptor agonists and human coronary artery reactivity in vitro: crossover comparisons of 5-HT and sumatriptan with rizatriptan and L-741,519. Br J Clin Pharmacol. 1996 Oct;42(4):431-41. Pubmed
  4. Sciberras DG, Polvino WJ, Gertz BJ, Cheng H, Stepanavage M, Wittreich J, Olah T, Edwards M, Mant T: Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist. Br J Clin Pharmacol. 1997 Jan;43(1):49-54. Pubmed
  5. Williamson DJ, Hill RG, Shepheard SL, Hargreaves RJ: The anti-migraine 5-HT agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs. Br J Pharmacol. 2001 Aug;133(7):1029-34. Pubmed
  6. Wackenfors A, Jarvius M, Ingemansson R, Edvinsson L, Malmsjo M: Triptans induce vasoconstriction of human arteries and veins from the thoracic wall. J Cardiovasc Pharmacol. 2005 May;45(5):476-84. Pubmed
  7. Wellington K, Plosker GL: Rizatriptan: an update of its use in the management of migraine. Drugs. 2002;62(10):1539-74. Pubmed
  8. Wellington K, Jarvis B: Spotlight on rizatriptan in migraine. CNS Drugs. 2002;16(10):715-20. Pubmed
  9. Ikemoto F, Toru T, Aijima H, Natsumeda Y: [Rizatriptan (Maxalt), a new entity of triptan for migraine: pharmacology and therapeutic relevance] Nippon Yakurigaku Zasshi. 2004 Apr;123(4):295-302. Pubmed

2. 5-hydroxytryptamine receptor 1B

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: agonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 1B P28222 Details

References:

  1. Wellington K, Plosker GL: Rizatriptan: an update of its use in the management of migraine. Drugs. 2002;62(10):1539-74. Pubmed
  2. Wellington K, Jarvis B: Spotlight on rizatriptan in migraine. CNS Drugs. 2002;16(10):715-20. Pubmed
  3. Ikemoto F, Toru T, Aijima H, Natsumeda Y: [Rizatriptan (Maxalt), a new entity of triptan for migraine: pharmacology and therapeutic relevance] Nippon Yakurigaku Zasshi. 2004 Apr;123(4):295-302. Pubmed
  4. Pauwels PJ, Palmier C, Dupuis DS, Colpaert FC: Interaction of 5-HT1B/D ligands with recombinant h 5-HT1A receptors: intrinsic activity and modulation by G-protein activation state. Naunyn Schmiedebergs Arch Pharmacol. 1998 May;357(5):490-9. Pubmed
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  6. Williamson DJ, Hill RG, Shepheard SL, Hargreaves RJ: The anti-migraine 5-HT agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs. Br J Pharmacol. 2001 Aug;133(7):1029-34. Pubmed
  7. Wackenfors A, Jarvius M, Ingemansson R, Edvinsson L, Malmsjo M: Triptans induce vasoconstriction of human arteries and veins from the thoracic wall. J Cardiovasc Pharmacol. 2005 May;45(5):476-84. Pubmed

3. 5-hydroxytryptamine receptor 1F

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: agonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 1F P30939 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  2. Villalon CM, Centurion D, Valdivia LF, de Vries P, Saxena PR: Migraine: pathophysiology, pharmacology, treatment and future trends. Curr Vasc Pharmacol. 2003 Mar;1(1):71-84. Pubmed
  3. Villalon CM, Centurion D, Valdivia LF, De Vries P, Saxena PR: An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210. Pubmed
  4. Wainscott DB, Johnson KW, Phebus LA, Schaus JM, Nelson DL: Human 5-HT1F receptor-stimulated [35S]GTPgammaS binding: correlation with inhibition of guinea pig dural plasma protein extravasation. Eur J Pharmacol. 1998 Jul 3;352(1):117-24. Pubmed
  5. Goadsby PJ, Classey JD: Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience. 2003;122(2):491-8. Pubmed

Enzymes

1. Amine oxidase [flavin-containing] A

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Amine oxidase [flavin-containing] A P21397 Details

References:

  1. Iwasa T, Sano H, Sugiura A, Uchiyama N, Hara K, Okochi H, Nakagawa K, Yasumori T, Ishizaki T: An in vitro interethnic comparison of monoamine oxidase activities between Japanese and Caucasian livers using rizatriptan, a serotonin receptor 1B/1D agonist, as a model drug. Br J Clin Pharmacol. 2003 Nov;56(5):537-44. Pubmed
  2. Van Haarst AD, Van Gerven JM, Cohen AF, De Smet M, Sterrett A, Birk KL, Fisher AL, De Puy ME, Goldberg MR, Musson DG: The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers. Br J Clin Pharmacol. 1999 Aug;48(2):190-6. Pubmed

2. Cytochrome P450 1A2

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 1A2 P05177 Details

References:

  1. Sternieri E, Coccia CP, Pinetti D, Ferrari A: Pharmacokinetics and interactions of headache medications, part I: introduction, pharmacokinetics, metabolism and acute treatments. Expert Opin Drug Metab Toxicol. 2006 Dec;2(6):961-79. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:12